 Connection
Frits Van Rhee to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Frits Van Rhee has written about Drug Resistance, Neoplasm.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.381 |
|
|
|
-
Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, Hungria VTM, Puig N, Ren K, Silar J, Enwemadu V, Cherepanov D, Leleu X. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study. Eur J Haematol. 2024 Aug; 113(2):190-200.
Score: 0.200
-
Qiang YW, Ye S, Chen Y, Buros AF, Edmonson R, van Rhee F, Barlogie B, Epstein J, Morgan GJ, Davies FE. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood. 2016 12 22; 128(25):2919-2930.
Score: 0.119
-
Tricot G, Barlogie B, Van Rhee F. Treatment advances in multiple myeloma. Br J Haematol. 2004 Apr; 125(1):24-30.
Score: 0.050
-
Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003 Jan; 31(1):73-80.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|